Form 4: Avalo Therapeutics Director Acquires Stock Options

Avalo Therapeutics Director Michael Heffernan acquired stock options for 29,500 shares of common stock.

Summary

• Michael Heffernan, a Director at Avalo Therapeutics, Inc., was granted stock options on June 2, 2026.
• The options grant the right to purchase 29,500 shares of common stock at an exercise price of $13.96 per share.
• These options vest 100% on the first anniversary of the grant date, provided Mr. Heffernan remains a director.
• The expiration date for these options is June 2, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard compensation event for a director rather than a significant financial or strategic development for the company.

Positives

• Director Heffernan's acquisition of stock options aligns his interests with shareholders, potentially indicating confidence in the company's future performance.
• The vesting schedule encourages continued service and commitment from the director.

Risks

• The exercise price of $13.96 per share for the stock options suggests a potential expectation of the stock price reaching or exceeding this level for the options to be profitable.
• If the company's stock price does not appreciate significantly, the options may not be exercised, and the intended incentive may not materialize.

Future Outlook

The stock options granted to Director Heffernan vest on the first anniversary of the grant date, indicating a forward-looking incentive tied to continued service and potential future stock performance.

Industry Context

StockSavvy.ai notes that the granting of stock options to directors is a common practice in the biotechnology and pharmaceutical sectors, aligning executive and board interests with shareholder value creation through potential stock price appreciation.

Stakeholder Impact

• Shareholders: The alignment of director incentives with stock performance may positively influence long-term shareholder value.
• Employees: Standard compensation practices for directors can contribute to overall company morale and governance structure.
• Management: Reinforces standard executive compensation practices within the industry.

Next Steps

• Director Michael Heffernan is expected to continue his service to Avalo Therapeutics, Inc.
• The stock options will vest on June 2, 2027, subject to continued service.
• The options can be exercised anytime between June 2, 2027, and June 2, 2036.

Key Dates

Keywords

Avalo Therapeutics, AVTX, Form 4, Stock Options, Director Compensation, Beneficial Ownership, Securities Exchange Act